![Chris de Jonghe](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Chris de Jonghe
Direttore/Membro del Consiglio presso FORMAC Pharmaceuticals NV
Posizioni attive di Chris de Jonghe
Società | Posizione | Inizio | Fine |
---|---|---|---|
Participatiemaatschappij Vlaanderen NV
![]() Participatiemaatschappij Vlaanderen NV Investment ManagersFinance Participatiemaatschappij Vlaanderen NV (PMV) is a private equity/venture capital firm, a subsidiary of Region of Flanders founded in 1995. Participatiemaatschappij Vlaanderen NV is headquartered in Brussels, Belgium. | Investitore di Private Equity | 01/12/2012 | - |
FORMAC Pharmaceuticals NV
![]() FORMAC Pharmaceuticals NV Pharmaceuticals: GenericHealth Technology FORMAC Pharmaceuticals NV engages in drug delivery and development services. The firm applies its silica based drug delivery platforms for improving in vivo performance of poorly soluble compounds. The company was founded by Johan A. Martens, Paul Joseph Rutgeerts, Guy Van den Mooter and Jan Baptist Van Humbeeck in 2007 and is headquartered in Heverlee, Belgium. | Direttore/Membro del Consiglio | - | - |
FlandersBio vzw
![]() FlandersBio vzw Miscellaneous Commercial ServicesCommercial Services FlandersBio vzw is a life sciences cluster organization based in Flanders, Belgium. FlandersBio creates value by organizing networking and training activities, supporting internationalization, providing services, and building expertise. The Belgian company was founded by Jean Marie Stassen. | Corporate Officer/Principal | - | - |
Vesalius Biocapital I SA SICAR
![]() Vesalius Biocapital I SA SICAR Investment ManagersFinance Vesalius Biocapital I SA Sicar focuses on healthcare companies that are in the early stage or that are corporate spin-offs. The fund invests mainly in Europe with a more precise focus on the Benelux countries. Vesalius invests up to EUR 10 million and may invest a few hundred thousand euros in a seed project. | Direttore/Membro del Consiglio | - | - |
Vesalius Biocapital II SA SICAR
![]() Vesalius Biocapital II SA SICAR Investment ManagersFinance Vesalius Biocapital II SA Sicar focuses on healthcare companies that are in the early stage or that are corporate spin-offs. The fund invests mainly in Europe with a more precise focus on the Benelux countries. Vesalius invests up to EUR 10 million and may invest a few hundred thousand euros in a seed project. | Direttore/Membro del Consiglio | - | - |
MyCartis NV
![]() MyCartis NV BiotechnologyHealth Technology MyCartis NV develops technologies for healthcare personalization needs. It offers Evalution, a multiplex analysis platform to develop protein and nucleic-acid based clinical biomarkers. The company provides disruptive solutions in the fields of clinical and translational research for various applications in the detection of proteins and nucleic acids, such as sandwich immunoassays, antibody assays, genotyping assays, and mutation analysis assays to customers and partners. It offers products for various disease areas, including cell signalling, cardiovascular, oncology, and preeclampsia. The company was founded by Koen Kas in August 2004 and is headquartered in Ghent, Belgium. | Direttore/Membro del Consiglio | - | - |
Oncode BV
![]() Oncode BV Investment ManagersFinance Oncode BV is a venture capital firm, a subsidiary of Oncode Institute, founded in 2018. Oncode BV is headquartered in Utrecht. | Corporate Officer/Principal | 01/05/2020 | - |
Storia della carriera di Chris de Jonghe
Precedenti posizioni note di Chris de Jonghe
Società | Posizione | Inizio | Fine |
---|---|---|---|
CELYAD ONCOLOGY SA | Direttore/Membro del Consiglio | 01/01/2013 | 05/05/2017 |
Independent Dir/Board Member | 02/06/2015 | 05/05/2017 | |
reMYND NV
![]() reMYND NV Miscellaneous Commercial ServicesCommercial Services reMYND NV engages in the development of disease-modifying treatments against alzheimer's, parkinson's, diabetes and other protein misfolding disorders. Its drug and development unit focuses on innovative, disease-modifying drugs for treating degenerative disorders. The company was founded by Fred Van Leuven, Stefaan Wera and Joris Winderickx in 2002 and is headquartered in Leuven, Belgium. | Direttore/Membro del Consiglio | - | - |
░░░░░ ░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░░░░░ ░░ | ░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
Formazione di Chris de Jonghe
University of Antwerp | Doctorate Degree |
Statistiche
Distribuzione geografica
Belgio | 13 |
Lussemburgo | 3 |
Paesi Bassi | 2 |
Posizioni
Director/Board Member | 10 |
Corporate Officer/Principal | 2 |
Private Equity Investor | 1 |
Settori
Health Technology | 7 |
Finance | 5 |
Commercial Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
CELYAD ONCOLOGY SA | Health Technology |
BIOTALYS NV | Process Industries |
Aziende private | 12 |
---|---|
Participatiemaatschappij Vlaanderen NV
![]() Participatiemaatschappij Vlaanderen NV Investment ManagersFinance Participatiemaatschappij Vlaanderen NV (PMV) is a private equity/venture capital firm, a subsidiary of Region of Flanders founded in 1995. Participatiemaatschappij Vlaanderen NV is headquartered in Brussels, Belgium. | Finance |
MyCartis NV
![]() MyCartis NV BiotechnologyHealth Technology MyCartis NV develops technologies for healthcare personalization needs. It offers Evalution, a multiplex analysis platform to develop protein and nucleic-acid based clinical biomarkers. The company provides disruptive solutions in the fields of clinical and translational research for various applications in the detection of proteins and nucleic acids, such as sandwich immunoassays, antibody assays, genotyping assays, and mutation analysis assays to customers and partners. It offers products for various disease areas, including cell signalling, cardiovascular, oncology, and preeclampsia. The company was founded by Koen Kas in August 2004 and is headquartered in Ghent, Belgium. | Health Technology |
FORMAC Pharmaceuticals NV
![]() FORMAC Pharmaceuticals NV Pharmaceuticals: GenericHealth Technology FORMAC Pharmaceuticals NV engages in drug delivery and development services. The firm applies its silica based drug delivery platforms for improving in vivo performance of poorly soluble compounds. The company was founded by Johan A. Martens, Paul Joseph Rutgeerts, Guy Van den Mooter and Jan Baptist Van Humbeeck in 2007 and is headquartered in Heverlee, Belgium. | Health Technology |
reMYND NV
![]() reMYND NV Miscellaneous Commercial ServicesCommercial Services reMYND NV engages in the development of disease-modifying treatments against alzheimer's, parkinson's, diabetes and other protein misfolding disorders. Its drug and development unit focuses on innovative, disease-modifying drugs for treating degenerative disorders. The company was founded by Fred Van Leuven, Stefaan Wera and Joris Winderickx in 2002 and is headquartered in Leuven, Belgium. | Commercial Services |
Vesalius Biocapital I SA SICAR
![]() Vesalius Biocapital I SA SICAR Investment ManagersFinance Vesalius Biocapital I SA Sicar focuses on healthcare companies that are in the early stage or that are corporate spin-offs. The fund invests mainly in Europe with a more precise focus on the Benelux countries. Vesalius invests up to EUR 10 million and may invest a few hundred thousand euros in a seed project. | Finance |
FlandersBio vzw
![]() FlandersBio vzw Miscellaneous Commercial ServicesCommercial Services FlandersBio vzw is a life sciences cluster organization based in Flanders, Belgium. FlandersBio creates value by organizing networking and training activities, supporting internationalization, providing services, and building expertise. The Belgian company was founded by Jean Marie Stassen. | Commercial Services |
Amakem NV
![]() Amakem NV Medical/Nursing ServicesHealth Services Amakem NV operates as a biopharmaceutical company. It uses kinase inhibitors for treatments of bowel, eye, and lung diseases. The company was founded by Jack Elands, Dirk Leysen, Olivier Raynald Defert, and Nadya Kaval on July 22, 2009 and is headquartered in Diepenbeek, Belgium. | Health Services |
Multiplicom NV
![]() Multiplicom NV Medical SpecialtiesHealth Technology Multiplicom NV develops, manufactures, and commercializes molecular diagnostics solutions. It specializes in pathology laboratories, next generation sequencing, multiplex amplification of specific targets for resequencing, genetics, assay kits, clinical laboratories, and personalized medicine. The company was founded by Chris De Jonghe in 2011 and is headquartered in Niel, Belgium. | Health Technology |
Vesalius Biocapital II SA SICAR
![]() Vesalius Biocapital II SA SICAR Investment ManagersFinance Vesalius Biocapital II SA Sicar focuses on healthcare companies that are in the early stage or that are corporate spin-offs. The fund invests mainly in Europe with a more precise focus on the Benelux countries. Vesalius invests up to EUR 10 million and may invest a few hundred thousand euros in a seed project. | Finance |
eSATURNUS NV
![]() eSATURNUS NV BiotechnologyHealth Technology eSATURNUS NV provides healthcare services for hospitals, doctors, nursing staff, and patients. The company was founded by Thomas Koninckx and Bob Koninckx on April 6, 2007 and is headquartered in Leuven, Belgium. | Health Technology |
Confo Therapeutics NV
![]() Confo Therapeutics NV Pharmaceuticals: MajorHealth Technology Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium. | Health Technology |
Oncode BV
![]() Oncode BV Investment ManagersFinance Oncode BV is a venture capital firm, a subsidiary of Oncode Institute, founded in 2018. Oncode BV is headquartered in Utrecht. | Finance |
- Borsa valori
- Insiders
- Chris de Jonghe
- Esperienza